

PATIENT INFORMATION:

Patient Name: _____ DOB: _____ Phone: _____

Patient Status: New to Therapy Continuing Therapy Next Treatment Date: _____**DIAGNOSIS AND ICD-10 CODE:**Diagnosis: Gaucher Disease
 Type 1 Type 3

ICD-10 Code: E75.22

Patient Weight: _____ lbs. (required) Allergies: _____

PRESCRIPTION:Cerezyme: Dose: 60units/kg IV every 2 weeks x1 year
 Other Dosage: _____Pre-Medication Orders: Tylenol 1000mg PO
 Cetirizine 10mg PO/IV
 Benadryl 25 mg PO
 Solumedrol _____ mg IV
 Other: _____

Prescriber to monitor for antibody formation during 1st year of treatment.

Lab Orders: _____ Lab Frequency: _____

Other orders: _____

PROVIDER INFORMATION:

By signing this form, you authorize US Infusions and its staff to handle prior authorizations, coordinate with insurance providers, and determine the patient's preferred site of care.

Provider Name: _____ Signature: _____ Date: _____

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____

PATIENT INFORMATION:

Patient Name: _____ DOB: _____ Phone: _____

REQUIRED ASSOCIATED DOCUMENTATION:

- Signed and completed order (MD/prescriber to complete page 1)
- Patient demographic information and insurance information
- Patient's medication list
- Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
- Does the patient have symptomatic Gaucher Disease as evidence by moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, and/or splenomegaly? Yes No
- Does the patient have a history of failure or intolerance to VPRIV? Yes No
- Labs and/or test results to support diagnosis
 - CBC, Hepatic Function Tests
- Other medical necessity: _____

CLINICAL DOCUMENTATION REQUIRED

- Glucocerebrosidase enzyme activity (Must show low enzyme activity consistent with Gaucher disease)
- GBA genetic testing (GBA1 mutation analysis)